Nephros (NEPH) Q3 2024 earnings summary

Executive summary

• Achieved first profitable quarter in Q3 2024, with net income of $0.2 million, reversing a net loss of $0.2 million in Q3 2023.

• Net revenue for Q3 2024 was $3.5 million, up 8% sequentially from Q2 2024 but down 6% year-over-year.

• Profitability was driven by cost management, operational improvements, and a rebound in emergency response orders.

• Operating expenses declined 19% year-over-year, reflecting lower bonus accruals, commissions, and stock compensation.

• For the nine months ended September 30, 2024, net revenues fell 6% to $10.3 million, with a net loss of $275,000, a significant improvement from a $921,000 loss in the prior year period.

Financial highlights

• Gross margin improved to 61% in Q3 2024 from 59% in Q3 2023, aided by better supplier terms.

• Adjusted EBITDA for Q3 2024 was $295,000, up from $11,000 in Q3 2023.

• SG&A expenses reduced to $1.7 million from $2.1 million year-over-year.

• Cash and cash equivalents were $2.5 million as of September 30, 2024, down from $4.3 million at year-end 2023, due to earlier operating losses and inventory investment.

• Q3 2024 EPS was $0.02 (basic and diluted), compared to $(0.02) in Q3 2023.

Outlook and guidance

• Management expects current cash balances and operational focus to fund the business for at least the next 12 months.

• Digital support tools for filter installation are being rolled out, with full deployment targeted for Q1 2025.

• Strategic investments planned in product pricing, operational efficiencies, and expansion opportunities.

• The company is investing in inventory to support anticipated higher sales volumes.

• If operating results underperform, further cost reductions may be implemented, including headcount and R&D cuts.